Download Botanix Pharmaceutical Investor Factsheet

Botanix is a medical dermatology company using a
novel drug active and proven drug delivery technology
to develop prescription treatments for serious skin
diseases, including acne, psoriasis and atopic
dermatitis.
It has licensed a novel drug delivery technology known
as Permetrex™ which is designed to deliver
pharmaceuticals into the skin more effectively than
other approaches. Botanix is preparing for the first
human trials delivering synthetic cannabidiol to the skin.
Cannabidiol is currently being studied by many
pharmaceutical companies for the treatment of
epilepsy, pain, arthritis and schizophrenia amongst
other indications, but Botanix plans to be the first
company to develop synthetic cannabidiol for skin
diseases. Cannabidiol has been shown in pre-clinical
studies to have a unique mechanism of action in skin
disease, along with a benign side effect profile.
Botanix’s target drug is very poorly absorbed if delivered orally
(only about 6% gets into the blood stream), so Botanix intends
on utilising a novel skin drug delivery technology called
Permetrex™, which is designed to deliver pharmaceuticals into
the skin more effectively than other approaches. The technology
is particularly useful as:

Permetrex™ does not utilise chemicals which have a tendency to dry the skin and are therefore not desirable
for diseases such as acne, psoriasis and atopic dermatitis;

Permetrex™ facilitates the rapid delivery of active pharmaceutical ingredients across protective layer of the skin
and into the lower layers where the drug targets are situated;

Permetrex™ can accommodate other formulation ingredients, which can selectively leave parts of the
formulation on the skin in a protective coating for extended absorption and/or protection of the skin.

Significant unmet patient needs: There has been little
innovation in the field of acne treatment and there
remains unmet patient and treatment need, including:
 the need for a topical product that inhibits
production of oil or lipids by the sebaceous glands;
novel actives, including a synthetic form of cannabidiol
which has an established safety and efficacy profile in
other diseases

Novel treatments for acne with a growing evidence
base: Cannabidiol has a unique mechanism of action
that addresses the 4 key pathologies of acne –
excessive oil production, infection, inflammation and
over-proliferation of skin cells

Strong management team: Botanix is rapidly
advancing under a proven board and management
team that have more than 10 FDA approvals between
them, and a successful track record on ASX

Path to market: Topical product applications are more
efficient and cost effective than oral or injectable
delivery
 antibiotic-independent mechanisms for reducing
acne colonisation and infection
 an agent with the efficacy of the leading oral
product (isotretinoin or 'Accutane'), but which is
potentially free of its serious side effects.
BTX1503 has the potential to meet these significant
unmet patient needs

Proprietary drug delivery system: Botanix has the
exclusive global rights to use Permetrex™ for a class of
Botanix Pharmaceuticals’ lead product under development (BTX1503) is a topically applied gel for the treatment of
serious acne which utilises the novel synthetic cannabidiol active, delivered using the Permetrex™ drug delivery
technology. Pre-clinical work has shown that a topical formulation if delivered effectively to the target organs in the
skin, may provide a new option for patients where existing anti-bacterial and inflammation targeting medicines have
failed.
There is a significant unmet patient need for effective therapies in the global acne market, given the relatively few
new products being developed and the recent withdrawal of products from the market, due to their significant side
effect problems.
Ticker Code
BOT
Share price
$0.02
Shares on Issue
408.8m
Market Capitalisation (undiluted, at issue price)
$8.1m
Debt
$0.0m
Cash raised
$3.5m
Graham Griffiths
Matthew Callahan
Chairman
Executive Director
Experienced ASX director and CEO with 39
years experience in technology
commercialisation and sales. Former Managing
Director of ipernica Ltd, now Nearmap
(ASX:NEA) and director of Pointerra Ltd
(ASX:3DP).
Founding CEO of iCeutica Inc and Churchill
Pharmaceuticals with more than 20 years life
sciences, IP and investment management
experience. Also a director of Glycan Bioscience
LLC and Orthocell (ASX:OCC).
Dr H. William Bosch
Robert Towner
Executive Director/Chief
Scientific Adviser
Non-Executive Director
More than 20 years of experience in the
Mr Towner was a founding Executive Director
pharmaceutical industry developing products
of ASX listed bioMD Limited and has over 20
for FDA approvals using drug delivery
years' corporate advisory and executive
technologies at Elan Corporation and iCeutica
experience.
Inc. Former co-founder of NanoSystems LLC
and coinventor of Nanocrystal and SoluMatrix™
technology platforms.
Botanix Pharmaceuticals is seeking to list on the Australian Securities Exchange. In April 2016, Bone Medical
(ASX: BNE) entered into an agreement to acquire 100 percent of Botanix to facilitate Botanix’s listing.
As part of the public offering, Botanix is seeking to raise $3 million (with oversubscriptions up to $500,000) under
the offer at a 2 cent capital raising.
Event
 `
Date
Announcement of Acquisition
21 March 2016
Despatch Notice of Meeting
13 May 2016
Lodgement of Prospectus and Offer Open
13 May 2016
Shareholder Meeting to Approve Acquisition
14 June 2016
Suspension from Trading
14 June 2016
Offer Close
27 June 2016
Expected date for Shares to be reinstated to trading on ASX
15 July 2016
For more information on Botanix Pharmaceuticals, please visit www.botanixpharma.com

Matthew Callahan
+1 215 767 4184
[email protected]

James Mcglew
08 9224 6866
[email protected]

Rebecca Wilson
03 8866 1216
[email protected]

Arthur Chan
02 9237 2805
[email protected]